Osteoporosis Drug May Prevent Memory Loss

Susan Farley
Published Online: Friday, July 1, 2005

In a study of the drug raloxifene (Evista), researchers at the San Francisco VA Medical Center found that, while the drug helps prevent osteoporosis in women, it also may help prevent age-related memory loss. More than 7700 women participated in the study, taking 60 or 120 mg of raloxifene or placebo for 3 years. In addition to preventing osteoporosis, the drug has been used to treat breast cancer, acting like estrogen in some tissues and like antiestrogen in others. Although scientists have been unable to determine how raloxifene affects memory, they found that those taking the 120-mg dose had a 33% lower risk of developing mild cognitive impairment, compared with those taking the 60-mg dose or placebo. They also noticed a slight reduction in the risk of Alzheimer's disease.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues